Puskesmas Ciketingudik

Primary Health Care

COVID-19

WestVac Biopharma

condition

allSponsorName

Sichuan University

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of therecombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants aged 18 years and older who do not have a known history of SARS-CoV-2 infection but whose locations or circumstances put them at appreciable risk of acquiring COVID-19 or SARS-CoV-2 infection.

A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)

Primary Health Care | Puskesmas Ciketingudik

Site insights

Work at this site?

Active trials

A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)

Trial sponsors